Fig 1.
Days after initial treatment vs. survival probability.
Correlations between days after initial treatment and survival probability in breast cancer patients (A) with high (> = 10.83 RKMP) vs. low (<10.83 RKMP) expression levels of CPT1A and (B) with or without mutations in CPT1A.
Fig 2.
Obesity status vs. lean body mass-corrected thymidine uptake.
Correlations between obesity status and lean body mass-corrected thymidine uptake value (SUVmean) in breast cancer patients separated by (A) pre-menopausal status and (B) post-menopausal status. A two-sided Pearson correlation and Mann-Whitney test was performed, and the corresponding r value determined statistical significance. SUV—standardized uptake value.
Fig 3.
Lean body mass-corrected mean standardized uptake value (SUVmean) in tumor; subcutaneous adipose tissue (SAT); visceral adipose tissue (VAT) at the level of the S2 vertebrae; liver; heart; and kidney separated by menopausal status (n = 33).
Fig 4.
Days after initial treatment vs. survival probability.
Correlations between days after initial treatment and survival probability in breast cancer patients with a high expression level of CPT1A (> = 10.83 RKMP) separated by menopausal status.
Fig 5.
Days after initial treatment vs. survival probability.
Correlations between days after initial treatment and survival probability in breast cancer patients with a low expression level of CPT1A (<10.83 RKMP) separated by menopausal status.
Fig 6.
Transcripts per million (TPM) of CPT1A separated by tissue types in which CPT1A is present.